Phillips, Adrienne A; Fields, Paul A; Hermine, Olivier; Ramos, Juan C; Beltran, Brady E; Pereira, Juliana 
; Wandroo, Farooq; Feldman, Tatyana; Taylor, Graham P; Sawas, Ahmed
Source: Haematologica. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, LEUCEMIA, LINFOMA, LINFÓCITOS T, QUIMIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PHILLIPS, Adrienne A et al. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica, v. 104, n. 5, p. 993-1003, 2019Tradução . . Disponível em: https://doi.org/10.3324/haematol.2018.205096. Acesso em: 13 jun. 2024.APA
Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., et al. (2019). Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica, 104( 5), 993-1003. doi:10.3324/haematol.2018.205096NLM
Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, Wandroo F, Feldman T, Taylor GP, Sawas A. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma [Internet]. Haematologica. 2019 ; 104( 5): 993-1003.[citado 2024 jun. 13 ] Available from: https://doi.org/10.3324/haematol.2018.205096Vancouver
Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, Wandroo F, Feldman T, Taylor GP, Sawas A. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma [Internet]. Haematologica. 2019 ; 104( 5): 993-1003.[citado 2024 jun. 13 ] Available from: https://doi.org/10.3324/haematol.2018.205096
